Advaxis, Inc. (NASDAQ:ADXS) insider Robert Petit sold 3,099 shares of the company’s stock in a transaction on Friday, January 29th. The shares were sold at an average price of $6.88, for a total transaction of $21,321.12. Following the completion of the sale, the insider now owns 130,557 shares of the company’s stock, valued at approximately $898,232.16. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Several equities analysts have issued reports on ADXS shares. FBR & Co. reissued a “buy” rating and issued a $34.00 price objective on shares of Advaxis in a research note on Wednesday, December 16th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Advaxis in a research note on Friday, October 9th. Finally, Janney Montgomery Scott reissued a “buy” rating and issued a $22.00 price objective on shares of Advaxis in a research note on Thursday, December 17th. Eight analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $31.00.

Advaxis, Inc. (NASDAQ:ADXS) opened at 7.00 on Tuesday. The stock’s 50 day moving average is $8.96 and its 200-day moving average is $12.50. The firm’s market capitalization is $236.38 million. Advaxis, Inc. has a 1-year low of $6.28 and a 1-year high of $30.13.

Other hedge funds recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in Advaxis by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 56,156 shares of the biotechnology company’s stock worth $565,000 after buying an additional 999 shares during the last quarter. Franklin Street Advisors increased its stake in Advaxis by 2.6% in the fourth quarter. Franklin Street Advisors now owns 144,900 shares of the biotechnology company’s stock worth $1,458,000 after buying an additional 3,700 shares during the last quarter. Creative Planning increased its stake in Advaxis by 158.6% in the fourth quarter. Creative Planning now owns 31,030 shares of the biotechnology company’s stock worth $312,000 after buying an additional 19,030 shares during the last quarter. Finally, Quantitative Systematic Strategies bought a new stake in Advaxis during the fourth quarter worth $302,000.

Advaxis, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the body’s natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen, and neutralizes regulatory T cells and myeloid-derived suppressor cells (NASDAQ:ADXS) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy, axalimogene filolisbac (ADXS-HPV), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer, Phase I/II in head and neck cancer, and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.

12 Month Chart for NASDAQ:ADXS

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.